BioCentury | Mar 25, 2020
Product Development

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday. The day also saw several companies begin work on...
BioCentury | Mar 19, 2020
Politics, Policy & Law

Former FDA Commissioners Gottlieb and McClellan propose actions to speed COVID-19 countermeasures

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday. They also...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

With a call for proposals by the Innovative Medicines Initiative for COVID-19 development programs and a new vaccine development consortium led by a Denmark-based biotech, Europe is ramping up its response to the coronavirus outbreak....
BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

It is a truth universally acknowledged, to borrow from Jane Austen, that a single-payer system will say “no” to new technology. If they accept it at all, they do so only when the prices are...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio  Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
Items per page:
1 - 10 of 793
BioCentury | Mar 25, 2020
Product Development

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday. The day also saw several companies begin work on...
BioCentury | Mar 19, 2020
Politics, Policy & Law

Former FDA Commissioners Gottlieb and McClellan propose actions to speed COVID-19 countermeasures

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday. They also...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

With a call for proposals by the Innovative Medicines Initiative for COVID-19 development programs and a new vaccine development consortium led by a Denmark-based biotech, Europe is ramping up its response to the coronavirus outbreak....
BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

It is a truth universally acknowledged, to borrow from Jane Austen, that a single-payer system will say “no” to new technology. If they accept it at all, they do so only when the prices are...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | Jan 30, 2020
Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio  Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
Items per page:
1 - 10 of 793